In Vitro Antimicrobial Findings for Fusidic Acid Tested Against Contemporary (2008–2009) Gram-Positive Organisms Collected in the United States

JMI Laboratories, North Liberty, Iowa, USA.
Clinical Infectious Diseases (Impact Factor: 8.89). 06/2011; 52 Suppl 7(suppl 7):S477-86. DOI: 10.1093/cid/cir163
Source: PubMed


Fusidic acid has a long history of consistent activity against staphylococcal pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Fusidic acid (CEM-102) was susceptibility tested against a surveillance study collection of 12,707 Gram-positive pathogens (2008-2009) from the United States. Reference broth microdilution method results demonstrated the following MIC(50/90) results: S. aureus (.12/.25 μg/mL), coagulase-negative staphylococci (.12/.25 μg/mL), enterococci (4/4 μg/mL), Streptococcus pyogenes (4/8 μg/mL), and viridans group Streptococcus spp. (>8/>8 μg/mL). At a proposed susceptible breakpoint (≤1 μg/mL), fusidic acid inhibited 99.7% of MRSA strains and 99.3% to 99.9% of multidrug-resistant phenotypes of S. aureus. Furthermore, S. aureus strains nonsusceptible to fusidic acid (.35%) generally had detectable resistance mechanisms (fusA, B, C, and E). Reviews of in vitro susceptibility test development confirm the accuracy and intermethod reproducibility of various fusidic acid methods. Fusidic acid is a promising oral therapy for staphylococcal skin and skin structure infections in the United States, where the contemporary S. aureus population remains without significant resistance.

1 Read
  • Source
    • "FA inhibits protein synthesis in bacteria and acts against many pathogens including Staphylococcus aureus, gram-positive anaerobic bacteria, Neisseria spp., and Bordetella pertussis [19]. It is used clinically as a topical application or systemic treatment, particularly in case of bone and joint infections or skin and soft tissue infections [19]. EF-G has five structural domains (DI–DV). "
    [Show abstract] [Hide abstract]
    ABSTRACT: tInhibition of growth of the malaria parasite Plasmodium falciparum by known translation-inhibitoryantibiotics has generated interest in understanding their action on the translation apparatus of thetwo genome containing organelles of the malaria parasite: the mitochondrion and the relic plastid (api-coplast). We report GTPase activity of recombinant EF-G proteins that are targeted to the organelles andfurther use these to test the effect of the EF-G inhibitor fusidic acid (FA) on the factor–ribosome interface.Our results monitoring locking of EF-G·GDP onto surrogate Escherichia coli ribosomes as well as multi-turnover GTP hydrolysis by the factor indicate that FA has a greater effect on apicoplast EF-G comparedto the mitochondrial counterpart. Deletion of a three amino acid (GVG) sequence in the switch I loop thatis conserved in proteins of the mitochondrial EF-G1 family and the Plasmodium mitochondrial factor, butis absent in apicoplast EF-G, demonstrated that this motif contributes to differential inhibition of the twoEF-Gs by FA. Additionally, the drug thiostrepton, that is known to target the apicoplast and proteasome,enhanced retention of only mitochondrial EF-G on ribosomes providing support for the reported effectof the drug on parasite mitochondrial translation.
    Molecular and Biochemical Parasitology 01/2013; 192(1). DOI:10.1016/j.molbiopara.2013.10.003 · 1.79 Impact Factor
  • Source
    • "Some authors have proposed that isolates with MIC ≤ 1.0 μg/mL are susceptible (S) and those with MIC ≥ 2.0 μg/mL are resistant (R) while others have proposed an MIC ≤ 0.5 μg/mL as the susceptible breakpoint [10] [12]. Most recently Jones et al. compared broth dilution, Etest MIC, and disk diffusion, and they proposed an MIC ≥ 4.0 μg/mL as the interpretive break point for resistance and ≤1.0 μg/mL for susceptibility [13]. For disk diffusion testing, EUCAST has set the 10 μg fusidic acid zone size for resistance at 24 mm, while Skov et al. recently proposed ≤18 mm for resistance and ≥21 mm as susceptible interpretive break points [10] [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fusidic acid is a common therapy for staphylococcal infections in Saudi Arabia, but reports have suggested high rates of resistance among clinical isolates. Susceptibility testing of S. aureus to fusidic acid is further complicated by the lack of consensus on mean inhibitory concentrations (MIC) and disk diffusion cutoffs to determine resistance. The purpose of this study was to determine the correlation between disk diffusion and Etest determined MIC susceptibility results in clinical isolates of S. aureus from a large academic hospital in Riyadh, Saudi Arabia. Our data demonstrate excellent correlation between Etest determined MIC and disk diffusion susceptibility data, using either previously proposed zone sizes of ≥21 mm as susceptible and ≤18 mm as resistant or the EUCAST recommended zone size of ≤24 mm for resistance, in an area with relatively high rates of fusidic acid resistance.
    International Journal of Microbiology 07/2012; 2012(7):391251. DOI:10.1155/2012/391251
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fusidic acid binds to elongation factor G (EF-G), preventing its release from the ribosome, thus stalling bacterial protein synthesis. In staphylococci, high-level fusidic acid resistance is usually caused by mutations in the gene encoding EF-G, fusA, and low-level resistance is generally caused by the horizontally transferable mechanisms fusB and fusC that have a putative protective role on EF-G. In addition, fusD is responsible for intrinsic resistance in Staphylococcus saprophyticus, and alterations in the L6 portion of rplF (fusE) have a role in fusidic acid resistance. Fusidic acid has been used in Europe and Australia for decades. More recently, it has also been used in other countries and regions, but not in the United States. Worldwide fusidic acid resistance has been slow to develop, and the level of resistance and genetic mechanisms responsible generally reflect the time since introduction, indications for treatment, route of administration, and prescribing practices.
    Clinical Infectious Diseases 06/2011; 52 Suppl 7(Supplement 7):S487-92. DOI:10.1093/cid/cir164 · 8.89 Impact Factor
Show more